
HCA Healthcare
HCA · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $107 bn
- Div. yield
- 1,0%
- Year to date
- +6,9%
Ratio score
based on 8 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
4 ✓ · 3 — · 1 ✕ · 2 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 15,4 | 13,7 | 25,1 |
| Forward P/E | 15,2 | — | 16,2 |
| PEG | 1,8 | — | 2,2 |
| P/S | 1,3 | 1,2 | 2,2 |
| EV/EBITDA | 9,7 | 9,0 | 17,3 |
| P/FCF | 17,5 | — | 19,5 |
| P/B | 422,1 | — | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 31 analysts
- Buy
- 18
- Hold
- 11
- Sell
- 2
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 6,73 | 7,27 | Up +8,0% |
| Q2 2026 | 7,54 | 7,62 | Up +1,0% |
| Q1 2026 | 7,21 | 7,15 | Down −0,8% |
| Q4 2025 | 7,53 | 8,14 | Up +8,0% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19,8 bn | 20,2 bn | 19,1 bn | 19,5 bn | 19,2 bn | 18,6 bn | 18,3 bn | 18,3 bn | 17,5 bn | 17,5 bn | 17,3 bn | 17,3 bn |
| EPS | 7,27 | 7,62 | 7,15 | 8,10 | 6,96 | 6,83 | 6,45 | 5,63 | 4,88 | 5,53 | 5,93 | 5,90 |
| Margin | 8,0% | 8,4% | 8,5% | 9,6% | 8,6% | 8,9% | 8,8% | 7,9% | 7,3% | 8,4% | 9,2% | 9,3% |
| FCF | 3,10 bn | 1,10 bn | 895 m | 870 m | 3,13 bn | 3,03 bn | 660 m | 1,27 bn | 2,32 bn | 690 m | 1,35 bn | 1,52 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $47,5 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| rossitto erica10 Nov 2026 · sale | $1,77 m | 3 500 | $505,81 |
| foster jon m6 Nov 2026 · sale | $730 101 | 1 484 | $491,98 |
| foster jon m6 Nov 2026 · sale | $3,11 m | 6 302 | $493,58 |
| foster jon m6 Nov 2026 · sale | $3,76 m | 7 595 | $494,91 |
| foster jon m6 Nov 2026 · sale | $1,33 m | 2 692 | $495,85 |
| foster jon m6 Nov 2026 · sale | $529 717 | 1 066 | $496,92 |
| foster jon m6 Nov 2026 · sale | $838 629 | 1 684 | $498,00 |
| foster jon m6 Nov 2026 · sale | $444 084 | 890 | $498,97 |
| schlosser michael j4 Nov 2026 · sale | $593 583 | 1 200 | $494,65 |
| foster jon m4 Nov 2026 · sale | $5,14 m | 10 000 | $514,07 |
| mcalevey michael r18 Feb 2026 · sale | $903 537 | 1 694 | $533,37 |
| berres jennifer11 Feb 2026 · sale | $2,11 m | 4 010 | $526,16 |
| berres jennifer11 Feb 2026 · sale | $2,02 m | 4 010 | $503,00 |
| wyatt christopher f.11 Feb 2026 · sale | $2,02 m | 4 000 | $505,00 |
| cuffe michael s.3 Feb 2026 · sale | $747 135 | 1 500 | $498,09 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 28 Dec 2010
- Website
- hcahealthcare.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
CVSCVS Health | $88,59 | 83★★★★★★★★★would consider | 10,4 | +6,7% | 2,6% |
SYKStryker Corporation | $310,72 | 72★★★★★★★★★would consider | 33,0 | +7,9% | 13,8% |
ELVElevance Health | $446,28 | 78★★★★★★★★★would consider | 18,1 | +3,6% | 2,5% |
MCKMcKesson | $1 105,04 | 72★★★★★★★★★would consider | 27,3 | +8,2% | 1,1% |
MDTMedtronic | $102,88 | 78★★★★★★★★★would consider | 25,1 | +9,8% | 13,9% |
Ratio — a score by our methodology, not an investment recommendation.




